Hypertensive cardiac hypertrophy
Conditions
Interventions
Health group:none
Control group:Conventional Western Medicine Treatment
experimental group:Conventional Western Medicine Treatment & Jiangfang Baoxin capsule
Sponsors
Wuxi Traditional Chinese Medicine Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) It meets the diagnostic criteria of hypertensive cardiac hypertrophy and the identification criteria of liver depression and blood deficiency and yin deficiency. (2) Meet the diagnostic criteria of primary hypertensive left ventricular hypertrophy disease as measured by blood pressure in the unified clinic, in patients with hypertension with liver depression, blood deficiency and yin deficiency evidence of vegetative hypertension or with phlegm and stasis. (3) Aged 18-80 years. (4) Voluntarily participated in this study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Age 80 years. (2) Patients with significant liver or kidney disorders or ALT, AST higher than ULN 1.5 times, Cr, BUN higher than ULN (including aortic coarctation, acute pulmonary embolism, pneumothorax, pneumonia, pleurisy, pericarditis, heart valve disease, severe neurosis, menopausal syndrome, hyperthyroidism, cervical spondylosis, biliary heart disease, gastric and esophageal reflux, costochondritis, etc.). (3) Patients with other cardiac critical illnesses such as combined malignant arrhythmia, severe heart valve disease, acute heart failure, etc. (4) Patients with a combination of other serious cardiopulmonary insufficiency, hepatic and renal insufficiency, endocrine, rheumatic immune, hematopoietic system, etc. (5) Patients with infection, active bleeding (such as peptic ulcer, hemorrhoid haemorrhage), trauma or surgery within the last 1 month (6) Patients with combined malignancy or AIDS or mental illness. (7) Patients preparing for pregnancy or women during pregnancy or lactation. (8) Patients with known hypersensitivity to the components of the drugs used in this study. (9) Patients who have participated or are participating in other clinical trials within the last three months (10) Patients who are unwilling to cooperate with the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood pressure;Serum metabolomics;Extent of left ventricular hypertrophy on cardiac ultrasound; | — |
Secondary
| Measure | Time frame |
|---|---|
| Scores for TCM syndromes;Blood pressure compliance rate; | — |
Countries
China
Contacts
Public Contactyaoyuanchun
Wuxi Traditional Chinese Medicine Hospital
Outcome results
None listed